Qualifyze announced $54 million in Series B funding from global software investorInsight Partners, with participation from existing investorsHV Capital,HarbourVest Partners,H14 andCherry Ventures. With the new funding, Qualifyze aims to expand its operations into the US market, continue investing in its go-to-market strategy, and enhance its technology to improve supplier risk management globally.

Qualifyze宣布从global software investorInsight Partners获得5400万美元的B系列资金，现有投资者HV Capital、HarbourVest Partners、H14和Cherry Ventures也参与了该项目。通过新的资金，Qualifyze旨在将其业务扩展到美国市场，继续投资于其上市战略，并增强其技术，以改善全球供应商风险管理。

.

.

Recognized for its global coverage of reliable and high-quality auditing services, Qualifyze offers an integrated audit management platform that streamlines compliance audits for Life Science companies. With a network of over 250 auditors and quality professionals worldwide, the company has ensured the highest quality compliance standards for over 1,200 companies to date by working alongside industry leaders such as Merck, Moehs, DSM, Olon, Siegfried, Teva, CordenPharma, Cipla, Dr.

Qualifyze以其可靠和高质量的审计服务在全球范围内得到认可，它提供了一个集成的审计管理平台，可以简化生命科学公司的合规审计。该公司在全球拥有250多名审计师和质量专业人员，通过与默克（Merck）、Moehs、帝斯曼（DSM）、奥隆（Olon）、西格弗里德（Siegfried）、梯瓦（Teva）、科登制药（CordenPharma）、西普拉（Cipla）等行业领军企业合作，确保了迄今为止1200多家公司的最高质量合规标准。

Reddy’s Laboratories, Sun Pharmaceuticals, Sandoz and Mallinckrodt Pharmaceuticals. .

雷迪实验室、太阳制药、山德士和马林克罗特制药。

Qualifyze’s platform provides a centralized system to manage every aspect of audits (GxP, ESG, ISO, etc.), including planning, execution, and CAPA follow-ups and closure. By leveraging one of the world’s largest databases of pre-existing audit reports and real-time supplier data, Qualifyze allows the quality, procurement, and supply chain functions to assess supplier performance and enable more accurate supplier risk profiling.

Qualifyze的平台提供了一个集中的系统来管理审核的各个方面（GxP、ESG、ISO等），包括规划、执行以及CAPA的跟进和关闭。Qualifyze利用世界上最大的现有审计报告和实时供应商数据数据库之一，使质量、采购和供应链职能部门能够评估供应商绩效，并实现更准确的供应商风险分析。

This enhances overall operational transparency and regulatory adherence and significantly reduces the time and administrative burden typically associated with these processes. .

这增强了总体运营透明度和法规遵从性，并大大减少了通常与这些流程相关的时间和管理负担。

As the Life Sciences industry evolves, drug manufacturers face increasing safety requirements in their supply chain, making supplier management as crucial as customer relations. According to Gartner’s 2024 findings, leading organizations are shifting from mere resilience to “antifragile” supply chains that leverage disruptions for competitive advantage.

随着生命科学行业的发展，药品制造商在其供应链中面临越来越多的安全要求，使得供应商管理与客户关系一样重要。根据Gartner 2024年的调查结果，领先的组织正在从单纯的弹性转向“反敏捷”的供应链，利用中断来获得竞争优势。

This shift highlights why effective supply chain risk management is now essential for ensuring long-term success in an increasingly uncertain environment. .

这种转变突显了为什么有效的供应链风险管理对于确保在日益不确定的环境中取得长期成功至关重要。

In response to this trend, Qualifyze drew on data from over 3,000 audits conducted in more than 85 countries to launch its first analytics solutions in 2023. This positioned the company as a key partner in strategic risk management, providing unique insights into global compliance trends and supply chain quality.

为了应对这一趋势，Qualifyze利用了在85个国家进行的3000多项审计的数据，于2023年推出了首个分析解决方案。这使公司成为战略风险管理的关键合作伙伴，为全球合规趋势和供应链质量提供了独特的见解。

These tools help drug manufacturers meet compliance standards, gain valuable insights into supplier performance, and manage risks, ultimately resulting in faster time-to-market, lower inventory levels, and reduced Costs of Goods Sold. .

这些工具有助于药品制造商达到合规标准，获得对供应商绩效的宝贵见解，并管理风险，最终缩短上市时间，降低库存水平，降低销售成本。

“We have come a long way from our roots as a third-party auditing organization,” said Dr. David Schneider, Founder and CEO of Qualifyze. “Expanding into the US market, forging strategic partnerships, and scaling our global operations are just the start. We’re doubling down on enhancing our platform to deliver even more powerful insights for Quality, Procurement, and Supply Chain teams.

“作为第三方审计组织，我们已经走过了漫长的道路，”Dr。Qualifyze创始人兼首席执行官大卫·施奈德（DavidSchneider）。“拓展美国市场、建立战略合作伙伴关系和扩大全球运营只是开始。我们正在加倍努力，加强我们的平台，为质量、采购和供应链团队提供更强大的见解。

With this funding, we’re positioned to not only lead in supplier risk management but also set new industry standards, driving long-term value and innovation for our clients worldwide.” .

有了这笔资金，我们不仅可以领导供应商风险管理，还可以制定新的行业标准，为全球客户带来长期价值和创新。”。

With the goal of accelerating supplier qualification and selection, Qualifyze started issuing a proprietary Quality Compliance Rating (QCR) certificate in 2024. The QCR functions like a scoring system, enabling drug manufacturers to quickly identify the most reliable partners while allowing those partners with superior compliance to stand out from their competitors.

为了加速供应商资格认证和选择，Qualifyze于2024年开始颁发专有质量合规评级（QCR）证书。QCR的功能类似于评分系统，使药品制造商能够快速识别最可靠的合作伙伴，同时使那些具有优异合规性的合作伙伴从竞争对手中脱颖而出。

Vote of confidence from investors

投资者的信任投票

In addition to expanding operations, this new funding will accelerate Qualifyze’s mission to become the key partner for strategic supplier risk management in Life Sciences by collecting actionable audit data from every supplier in the world, centralized within one digital platform.

除了扩大运营之外，这项新资金还将加速Qualifyze成为生命科学战略供应商风险管理的关键合作伙伴的使命，通过收集世界上每个供应商的可行审计数据，集中在一个数字平台上。

“Qualifyze has established itself as a trusted partner for Life Sciences companies by transforming how supplier risk management is approached. We are excited to support David and the Qualifyze team as they expand into the US market and further develop their audit management platform, delivering insights that drive operational excellence and compliance in a complex industry,” said Ryan Hinkle, Managing Director at Insight Partners.

Insight Partners董事总经理Ryan Hinkle表示：“Qualifyze通过改变供应商风险管理的方式，已成为生命科学公司值得信赖的合作伙伴。我们很高兴支持David和Qualifyze团队进军美国市场，进一步开发其审计管理平台，提供见解，推动复杂行业的卓越运营和合规性。”。

As part of the transaction, Hinkle will join Qualifyze’s board of directors. .

作为交易的一部分，欣克尔将加入Qualifyze的董事会。

https://www.bionity.com/en/news/1184414/qualifyze-raises-54m-to-boost-supplier-risk-management-in-life-sciences.html

https://www.bionity.com/en/news/1184414/qualifyze-raises-54m-to-boost-supplier-risk-management-in-life-sciences.html

Qualifyze raises $12m to transform supply chain compliance in pharma by leveraging tech and audit data

Qualifyze筹集1200万美元，通过利用技术和审计数据来改变制药行业的供应链合规性